Premium
MiRNAs as biomarkers of phenotype in neutral lipid storage disease with myopathy
Author(s) -
Pegoraro Valentina,
Missaglia Sara,
Marozzo Roberta,
Tavian Daniela,
Angelini Corrado
Publication year - 2020
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.26761
Subject(s) - myopathy , microrna , phenotype , skeletal muscle , medicine , biomarker , endocrinology , mitochondrial myopathy , biology , pathology , genetics , gene , mitochondrial dna
Background Neutral lipid storage disease with myopathy (NLSDM) is a rare lipid metabolism disorder. In this study, we evaluated some circulating miRNAs levels in serum samples and the MRI of three affected siblings. Methods Three members of one NLSDM family were identified: two brothers and one sister. Muscles of lower and right upper extremities were studied by MRI. Expression profile of miRNAs, obtained from serum samples, was detected using qRT‐PCR. Results Two brothers presented with progressive skeletal myopathy, while the sister had severe hepatosteatosis and diabetes. NLSDM patients showed a significant increase of muscle‐specific miRNAs expression compared with healthy subjects. We found a correlation between hepatic damage and elevation of miRNAs expression profile of liver origin. Conclusions The dysregulation of miRNAs might represent an indicator of skeletal and hepatic damage and it might be useful to monitor the progression of NLSDM.